SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Costco Wholesale Corp. engages in the provision of operation of membership warehouses through wholly owned subsidiaries. It operates through the following geographical segments: United States, Canada, and Other International Operations. The company was founded by James D. Sinegal and Jeffrey H. Brotman in 1983 and is headquartered in Issaquah, WA.

Costco Wholesale Corp

Costco is currently trending as investors monitor its resilience amid macroeconomic volatility and ongoing debates surrounding the impact of potential tariff refunds on retail pricing. The community remains focused on Costco's defensive strengths, with frequent discussions centered on its robust membership renewal rates, traffic growth, and valuation relative to the broader consumer staples sector.

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Wayne, PA.

Avalo Therapeutics Inc

Avalo Therapeutics is generating significant investor interest driven by high trading volumes, active momentum in its clinical-stage pipeline, and multiple analyst endorsements from firms like Guggenheim and HC Wainwright. Community discussion is focused on the high-stakes Phase 2 LOTUS trial readout expected in 2026 and ongoing debates regarding the company's financial risk profile versus the potential upside of its immunology platform.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is currently a focal point for the community due to renewed institutional interest, shifting ecosystem management, and ongoing discussions regarding its quantum-resistant technology. While some traders debate the asset's long-term viability following historic price volatility, active participants are heavily focused on potential regulatory catalysts and the ongoing expansion of its real-world asset (RWA) utility.

Schwab Strategic Trust - Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF is capturing investor attention as they rotate toward defensive, value-oriented positions amidst broader market volatility. The community is actively debating the fund's resilience, with many investors maintaining a long-term 'buy and hold' strategy despite recent stagnant performance, while others monitor the ETF's sector diversification and dividend growth potential as a reliable hedge.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as the community speculates on a major upcoming partnership announcement, with many pointing to a connection with Stellar or a potential collaboration with Ripple/XRP at an upcoming industry event. Investors are actively debating the project's long-term utility in global payroll and real-world adoption, balancing high-conviction sentiment against skepticism regarding its price performance and market volatility.

Arista Networks, Inc. engages in the development, marketing, and sale of cloud networking solutions. Its solutions include EOS, a set of network applications, and Gigabit Ethernet switching and routing platforms. Its product categories include Core, Cognitive Adjacencies, and Network Software and Services. The company was founded by Andreas Bechtolsheim, David Cheriton, and Kenneth Duda in November 2004 and is headquartered in Santa Clara, CA.

Arista Networks Inc

Arista Networks is currently trending due to intense volatility following a quarterly earnings report that featured a strong double beat on top and bottom lines but provided cautious forward revenue guidance. The community is actively debating whether the double-digit price decline is a baseless overreaction caused by market makers or a justified correction given the stock's high valuation and competitive concerns within the AI infrastructure sector.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending as investors weigh the potential impact of looming pharmaceutical tariffs, which are pushing the company to increase its U.S. manufacturing footprint. Simultaneously, the community is actively debating the company's aggressive M&A strategy, particularly its focus on expanding oncology and T-cell engager therapy pipelines, while keeping a watchful eye on patent litigation risks.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is trending as the community debates its long-term viability, with supporters pointing to upcoming regulatory clarity like the Clarity Act and existing infrastructure partnerships, while skeptics emphasize a prolonged downward price trend and lack of active communication from project leadership.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is a primary focal point of market discourse following the FDA approval of Foundayo, its once-daily oral GLP-1 weight-loss pill, which analysts view as a major step toward expanding the obesity treatment market through improved convenience and scalability. While community discussion remains intense regarding its competitive positioning against Novo Nordisks oral offerings, the broader pharma sector is also digesting the implications of potential new pharmaceutical tariff policies and ongoing M&A activity, keeping Eli Lillys valuation and long-term growth trajectory at the center of investor focus.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Biocryst Pharmaceuticals is seeing significant market activity and heightened community discourse driven by persistent acquisition rumors and notable institutional volume in after-hours trading. Traders are actively debating the stock's valuation relative to its rare disease pipeline, while observing unconventional trading patterns that have fueled speculation of a potential buyout.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Omeros (NASDAQ:OMER) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen raised Omeros from a "sell" rating to a "hold" rating in a report on Saturday...

HC Wainwright Brokers Increase Earnings Estimates for Omeros

Omeros Corporation (NASDAQ:OMER - Free Report) - HC Wainwright increased their Q1 2026 earnings per share estimates for shares of Omeros in a note issued to investors on Wednesday, April 1st. HC Wainwright analyst B. Folkes now anticipates that the biopharmaceutical company will earn ($0.40) per sha...

Omeros (NASDAQ:OMER)  Shares Down 6.5%   - Here's Why

Omeros (NASDAQ:OMER) Trading Down 6.5% - What's Next...

Omeros (NASDAQ:OMER) Shares Gap Up - Should You Buy?

Omeros (NASDAQ:OMER) Shares Gap Up - Should You Buy...

Omeros Sees Unusually Large Options Volume (NASDAQ:OMER)

Omeros Corporation (NASDAQ:OMER - Get Free Report) saw unusually large options trading on Wednesday. Stock investors bought 7,487 call options on the company. This represents an increase of...

Omeros (NASDAQ:OMER) Releases Earnings Results, Beats Estimates By $3.69 EPS

Omeros (NASDAQ:OMER - Get Free Report) issued its quarterly earnings data on Tuesday. The biopharmaceutical company reported $3.14 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $3.69...

<ul class="summary-bullets"><li>The company said that its fourth quarter results include a net gain of $237.6 million tied to the zaltenibart transaction with Novo Nordisk.</li><li>The company’s Yartemlea was approved by the U.S. Food and Drug Administration for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy in December.</li><li>The company is now looking forward to an approval for the therapy from the European Medicines Agency by mid-2026.</li></ul>Shares of Omeros Corporation (OMER) rose 5% after hours on Tuesday after the company expressed optimism for its deal with Danish drugmaker Novo Nordisk and regarding its other drugs.The company reported net income for the fourth quarter of $86.5 million, compared to a net loss of $31.4 million in the corresponding quarter of 2024.<h2 class="st-heading-2">Omeros Corp Deal With Novo</h2>The company said that its fourth quarter results include a net gain of $237.6 million tied to the zaltenibart transaction with Novo Nordisk. Under the deal valued up to $2.1 billion, the Danish drugmaker received exclusive global rights in all indications to develop and commercialize Omeros’s zaltenibart and certain related antibodies and products.The transaction was closed in November, triggering an upfront cash payment of $240 million. The company is now eligible to receive milestone payments and tiered royalties on annual global net sales of applicable products. &nbsp;<h2 class="st-heading-2">Remaining Lineup</h2>The company’s Yartemlea was approved by the U.S. Food and Drug Administration for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy in adults and in children ages two years and older in December. Commercial distribution and sales of Yartemlea in the U.S. began in January. The drug is now being prescribed to both adult and pediatric patients across both hospital and outpatient settings, the company said, while adding that it has engaged several of its workforce to engage directly with transplant centers across the United States.The company is now looking forward to an approval for the therapy from the European Medicine Agency by mid-2026.“Following FDA approval of Yartemlea with a broad label and no boxed warning, REMS, or required vaccinations, our commercial launch is well underway, and patients who urgently need the drug are now able to access it,” said Omeros CEO Gregory A. Demopulos. “Our partnership with Novo Nordisk expands the breadth of indications being pursued for zaltenibart and has provided — and should continue to provide — substantial operating capital... These successes are expected to fuel the development of a growing portfolio of commercial products from our robust pipeline as we target positive cash flow in 2027.”<h2 class="st-heading-2">How Omeros Corp Retail Traders React?</h2>On Stocktwits, retail sentiment around OMER stock jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘high’ to ‘extremely high’ levels.A Stocktwits user expressed optimism for the stock rallying on the next trading day.<stembedurl>https://www.stocktwits.com/Discovergems/message/649116149</stembedurl>Another user expressed optimism for Yartemlea, particularly if it gets approval in the EU.<stembedurl>https://www.stocktwits.com/AgentMulder/message/649115278</stembedurl><a href="https://stocktwits.com/symbol/OMER">OMER stock</a> has gained 28% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/mltx-stock-garners-retail-attention-on-buyout-speculation-positive-skin-condition-trial-data/cZE5EhaRIVu">MLTX Stock Garners Retail Attention On Buyout Speculation, Positive Skin Condition Trial Data</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Omeros Corporation logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

OMER Stock Surges 5% After Hours On Novo Nordisk Deal Windfall And Drug Launch Optimism

Omeros reported net income for the fourth quarter of $86.5 million, compared to a net loss of $31.4 million in the corresponding quarter of 2024.

Equity

Omeros reported net income for the fourth quarter of $86.5 million, compared to a net loss of $31.4 million in the corresponding quarter of 2024.


Omeros Q4 Earnings Call Highlights

Omeros (NASDAQ:OMER) executives highlighted two major successes in the fourth quarter of 2025 that they said marked a turning point for the company: closing a $240 million upfront asset sale and...

Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results

Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2025, which include: Net income...

Omeros (NASDAQ:OMER) Share Price Passes Above 200 Day Moving Average - Here's Why

Omeros (NASDAQ:OMER) Stock Passes Above Two Hundred Day Moving Average - What's Next...

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

OMER
Omeros Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest OMER News

OMEROmeros Corp